Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CHIMERIC ANTIGEN RECEPTOR BINDING SPECIFICALLY TO CD30 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/287049
Kind Code:
A1
Abstract:
The present invention relates to: a chimeric antigen receptor binding specifically to CD30; a polynucleotide encoding a protein of the chimeric antigen receptor; a vector carrying the polynucleotide; a cell transformed with the vector; and a cell therapy product or a pharmaceutical composition for treating cancer, each comprising the cell as an active ingredient. The chimeric antigen receptor according to the present invention comprises an extracellular domain of CD30 ligand that specifically binds to CD30. Therefore, cytotoxic T cells or natural killer cells transformed with a vector capable of overexpressing the chimeric antigen receptor have cytotoxicity specifically against CD30-expressing carcinomas, and thus can be effectively used as an immune cell therapeutic agent for cancer treatment.

Inventors:
CHIN HWA SUP (KR)
CHUN TAE HOON (KR)
YANG JUN (KR)
LEE CHANG HEE (KR)
LEE NA YOUNG (KR)
PARK IN BYUNG (KR)
KANG SEOK JIN (KR)
PARK SI WON (KR)
LEE HYEON JEONG (KR)
Application Number:
PCT/KR2022/008806
Publication Date:
January 19, 2023
Filing Date:
June 21, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
IMMUNOLOGICAL DESIGNING LAB INC (KR)
International Classes:
C07K14/705; A61K35/17; A61K48/00; A61P35/00; C07K14/725; C12N15/85
Domestic Patent References:
WO2020135559A12020-07-02
WO2021222927A12021-11-04
Foreign References:
KR20190124247A2019-11-04
US9790282B22017-10-17
CN107312097A2017-11-03
Other References:
LINDNER S. E, JOHNSON S. M., BROWN C. E., WANG L. D.: "Chimeric antigen receptor signaling: Functional consequences and design implications", SCIENCE ADVANCES, vol. 6, no. 21, 22 May 2020 (2020-05-22), pages 1 - 8, XP055975073, DOI: 10.1126/sciadv.aaz3223
Attorney, Agent or Firm:
HAN, Kwang Hyun (KR)
Download PDF: